American Cancer Society Reinstates Routine PSA Screening in Major Policy Shift
The American Cancer Society has revised its prostate cancer screening guidelines, moving away from individualized decision-making toward routine testing for most men. As STAT News reports, the update reflects new evidence suggesting that regular prostate-specific antigen blood tests can reduce mortality, reversing a 2010 decision that had largely relegated the biomarker to discretionary use.
Context from Industry Pulse
The shift by the American Cancer Society marks a significant pivot in oncology strategy, prioritizing early detection over previous concerns about overdiagnosis. By setting the high-risk threshold at 3.0 ng/ml, the society is challenging current laboratory standards that often overlook lower elevations. This change is particularly focused on addressing health disparities, as Black men face disproportionately higher death rates from prostate cancer. The inclusion of MRI and secondary biomarkers as prerequisites for biopsy reflects an attempt to modernize the screening process, utilizing newer diagnostic technologies to mitigate the risk of unnecessary surgery while still capturing aggressive malignancies that were previously missed under the 2010 discretionary model.
The updated recommendations establish a specific testing schedule based on age and risk factors. According to reporting from STAT News, men between 50 and 69 who are at average risk should now undergo PSA screening every two years. The guidelines also introduce more aggressive surveillance for high-risk populations, including Black men and those with significant family histories of the disease. These individuals are encouraged to begin annual screenings starting at age 45.
To address historical concerns regarding overdiagnosis and unnecessary biopsies, the new framework includes diagnostic safeguards. As STAT News notes, the society now advises that an elevated PSA level should be confirmed with a second reading. Following a confirmed high result, clinicians are encouraged to use MRI scans or additional biomarker testing before proceeding to a biopsy. This multi-step approach is intended to distinguish between aggressive cancers and slow-growing tumors that may not require immediate intervention.
The American Cancer Society has also clarified the threshold for concern, setting the high PSA cutoff at 3.0 nanograms per milliliter for men under 70. This represents a significant shift from the 4.0 level commonly used by many laboratories. By lowering this threshold, the organization aims to help primary care physicians identify potential cases earlier. However, the guidelines suggest that screening should remain individualized for men in their 70s and generally cease for those over 80 or with limited life expectancy.
While the American Cancer Society has modernized its stance based on 2025 evidence, other major health bodies have not yet followed suit. STAT News reports that the U.S. Preventive Services Task Force still recommends against population-wide screening, though the federal panel has indicated an update is forthcoming. The divergence highlights ongoing debates within the medical community regarding the balance between the benefits of early detection and the risks of overtreatment for low-risk, early-stage disease.
The Industry Pulse Bottom Line
The new ACS guidelines signal a return to proactive prostate cancer screening, prioritizing early intervention for high-risk groups while utilizing MRIs and secondary biomarkers to minimize the historical problem of overtreating low-risk cases.